Management of Retinal Vein Occlusion: Current Concepts

Seenu Hariprasad, MD

  • $129.95
  • ISBN 10 1617116165
  • ISBN 13 978-1617116162
  • 192 pp Hard Cover
  • Pub. Date: 2014
  • Order# 66162
Management of retinal venous occlusions (RVO) has changed dramatically in recent years. With an increase in medical information, technological advances, and clinical trials, ophthalmologists need a concise, updated reference. Management of Retinal Vein Occlusion: Current Concepts fills this current need in the market.

In Management of Retinal Vein Occlusion, Dr. Seenu Hariprasad is joined by multiple section editors to provide this easy-to-read and nicely formatted resource, which is divided into organized sections:

• Background: The epidemiology, risk factors, and classification of RVO
• History: Seven large clinical trials involving RVO and the pros and cons of earlier treatment modalities
• Anti-VEGF Therapies: The rationale and outcomes of large clinical trials
• Corticosteroid Therapies: The rationale and outcomes of various steroid treatment modalities
• Imaging: Case presentations and emerging technology that highlights the relationship between peripheral ischemia and macular edema
• Difficult cases: Combination therapies, management of recalcitrant cases, and surgical approaches for cases that do not respond to standard management
• Future of RVO: A summary overview of the subject and future directions

With an unparalleled list of contributors that are leaders in the retina field, Management of Retinal Vein Occlusion goes beyond the conclusions of clinical trials and delves deeper into practical recommendations for patient management in daily practice.

With abundant illustrations, fundus photographs, and concise tables that enhance the written text, Management of Retinal Vein Occlusion: Current Concepts is a valuable resource.
  • Dedication

  • About the Editor

  • About the Section Editors

  • Contributing Authors

  • Foreword by Harry W. Flynn Jr, MD

  • Introduction

  • $25.00

  • Chapter 1: Retinal Vein Occlusion

  • Kapil G. Kapoor, MD ; Sophie J. Bakri, MD

  • $25.00

  • Chapter 2: Retinal Vein Occlusion Clinical Trials

  • Dean Eliott, MD ; Yewlin E. Chee, MD

  • $25.00

  • Chapter 3: Anti-Vascular Endothelial Growth Factor Therapies For Retinal Vein Occlusion

  • Nancy M. Holekamp, MD ; Shaun T. Ittiara, MD

  • $25.00

  • Chapter 4: Corticosteroid Therapies In The Management Of Macular Edema Secondary To Retinal Vein Occlusion

  • Amol Kulkarni, MD ; Michael S. Ip, MD

  • $25.00

  • Chapter 5: Role Of Imaging In The Management Of Macular Edema Secondary To Retinal Vein Occlusion

  • Pearse A. Keane, MD, MSc, FRCOphth, MRCSI; Colin S. Tan, MBBS, FRCSEd (Ophth), MMed (Ophth); Michael A. Singer, MD; ; SriniVas R. Sadda, MD

  • $25.00

  • Chapter 6: Combination Therapy, Management Of Recalcitrant Cases, And Surgical Approaches

  • Eric W. Schneider, MD ; Tamer H. Mahmoud, MD, PhD

  • Financial Disclosures

  • Index

Seenu M. Hariprasad, MD is a Professor at the University of Chicago, Department of Ophthalmology and Visual Sciences, Pritzker School of Medicine in Illinois, where he serves as Chief of the Vitreoretinal Service.

After receiving his Bachelor of Arts degree from Cornell University in Ithaca, NY and graduating with Distinction in Neuroscience, Dr. Hariprasad went on to receive his Medical Degree from the University of Pennsylvania in Philadelphia, where he was elected into Alpha Omega Alpha. He completed both his transitional internship and ophthalmology residency at Baylor College of Medicine’s Cullen Eye Institute in Houston, TX, where he received numerous research awards. Dr. Hariprasad then spent 2 years at Washington University’s Barnes Retina Institute in St. Louis, MO, where he completed a Fellowship in the Diseases and Surgery of the Retina, Macula, and Vitreous.

Dr. Hariprasad is actively involved in clinical research, having been principal investigator or sub-investigator in nearly 50 national clinical trials evaluating new drugs, devices, and surgical innovations for age-related macular degeneration, retinal vascular occlusion, uveitis, endophthalmitis, and diabetic eye disease. His efforts in research have resulted in more than 140 peer-reviewed publications, meeting abstracts, and textbook chapters. He currently holds the position of Director of Ophthalmic Clinical Research at the University of Chicago.

In addition to serving on the Editorial Board for the American Journal of Ophthalmology, Dr. Hariprasad is also a scientific referee for 12 major ophthalmology journals. Additionally, he serves on the Editorial Board for OSLI Retina, Retinal Physician, and Ocular Surgery News. He is also co-founder of the CONNECT Network, a collaborative association of academic vitreoretinal specialists dedicated to furthering the vitreoretinal subspecialty through various research and educational endeavors.
Dr. Hariprasad has presented a vast number of lectures at scientific meetings, as well as guest lectureships both nationally and internationally. He has trained numerous residents and currently is Director of the Surgical Retina Fellowship Program at the University of Chicago.

Dr. Hariprasad is board certified by the American Board of Ophthalmology and is a member of the American Medical Association, American Academy of Ophthalmology, Macula Society, Retina Society, American Society of Retinal Specialists, Association for Research in Vision and Ophthalmology, Club Vit, and the Chicago Ophthalmological Society. From 2007 to present, the Consumer Research Council of America has selected him as one of “America’s Top Ophthalmologists.” Becker’s ASC Review has named him as one of “135 Leading Ophthalmologists in America,” and he is listed as one of Castle Connolly/US News & World Report “America’s Top Doctors.” In 2014, he was listed in the Chicago Magazine Biennial List of Outstanding Doctors. Dr. Hariprasad has received Honor Achievement Awards from both the American Academy of Ophthalmology and the American Society of Retina Specialists.

Sign up to receive

Book E-mail alerts

(no third party emails)